{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:49:49Z","timestamp":1764251389380},"reference-count":41,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,6,20]]},"DOI":"10.18632\/oncotarget.4148","type":"journal-article","created":{"date-parts":[[2015,9,15]],"date-time":"2015-09-15T06:31:06Z","timestamp":1442298666000},"page":"15321-15331","source":"Crossref","is-referenced-by-count":37,"title":["Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells"],"prefix":"10.18632","volume":"6","author":[{"given":"Nitu","family":"Bansal","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasun J.","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Biochemical and Cellular Pharmacology, Genentech, South San Fransisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Stein","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"DiPaola","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Bertino","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey, New Brunswick, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2015,5,15]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.pharmthera.2011.09.004","article-title":"Metformin and neoplasia: implications and indications","volume":"133","author":"Mousa","year":"2012","journal-title":"Pharmacology & therapeutics"},{"key":"2","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1158\/1055-9965.EPI-14-0056","article-title":"The use of metformin in patients with prostate cancer and the risk of death","volume":"23","author":"Azoulay","year":"2014","journal-title":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology"},{"key":"3","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1200\/JCO.2012.46.7043","article-title":"Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes","volume":"31","author":"Fleshner","year":"2013","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev-med-062613-093128","article-title":"Metformin in Cancer Treatment and Prevention","volume":"66","author":"Morris","year":"2015","journal-title":"Annual review of medicine"},{"key":"5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2011.09.022","article-title":"Metformin effects revisited","volume":"95","author":"Laferrere","year":"2012","journal-title":"Diabetes research and clinical practice"},{"key":"6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ejphar.2009.09.003","article-title":"Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats","volume":"623","author":"Fujiwara","year":"2009","journal-title":"European journal of pharmacology"},{"key":"7","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state","volume":"120","author":"Viollet","year":"2010","journal-title":"The Journal of clinical investigation"},{"key":"8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.canlet.2014.01.006","article-title":"Metformin: A metabolic disruptor and anti-diabetic drug to target human leukemia","volume":"346","author":"Peyron","year":"2014","journal-title":"Cancer letters"},{"key":"9","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effectandthrough a decrease of cyclin D1 level","volume":"27","author":"Bost","year":"2008","journal-title":"Oncogene"},{"key":"10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1101\/gad.12.1.21","article-title":"Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor","volume":"12","author":"Quertermous","year":"1998","journal-title":"Genes & development"},{"key":"11","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.3748\/wjg.v16.i36.4611","article-title":"High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients","volume":"16","author":"Xia","year":"2010","journal-title":"World journal of gastroenterology : WJG"},{"key":"12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1423-0127-16-33","article-title":"Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer","volume":"16","author":"Sun","year":"2009","journal-title":"Journal of biomedical science"},{"key":"13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacological research : the official journal of the Italian Pharmacological Society"},{"key":"14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/CS20110411","article-title":"Axl-dependent signalling: a clinical update","volume":"122","author":"Korshunov","year":"2012","journal-title":"Clinical science"},{"key":"15","doi-asserted-by":"crossref","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells","volume":"2","author":"Auberger","year":"2011","journal-title":"Oncotarget"},{"key":"16","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Kim","year":"2012","journal-title":"Nature genetics"},{"key":"17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ng.2362","article-title":"AXL and acquired resistance to EGFR inhibitors","volume":"44","author":"Ashworth","year":"2012","journal-title":"Nature genetics"},{"key":"18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U","article-title":"Cleavage and release of a soluble form of the receptor tyrosine kinase ARKand","volume":"168","author":"Basilico","year":"1996","journal-title":"Journal of cellular physiology"},{"key":"19","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/0008-5472.CAN-09-2997","article-title":"R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer","volume":"70","author":"Pine","year":"2010","journal-title":"Cancer research"},{"key":"20","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/onc.2013.57","article-title":"AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells","volume":"33","author":"Knutson","year":"2014","journal-title":"Oncogene"},{"key":"21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/sgtp.2.1.15114","article-title":"Vimentin: Central hub in EMT induction?","volume":"2","author":"Ivaska","year":"2011","journal-title":"Small GTPases"},{"key":"22","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1038\/onc.2010.509","article-title":"Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer","volume":"30","author":"Ivaska","year":"2011","journal-title":"Oncogene"},{"key":"23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16","volume":"33","author":"Bilo","year":"2010","journal-title":"Diabetes care"},{"key":"24","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.2337\/dc06-0997","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider","volume":"29","author":"Johnson","year":"2006","journal-title":"Diabetes care"},{"key":"25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CCO.0b013e32834d8155","article-title":"Metformin and cancer therapy","volume":"24","author":"Tanti","year":"2012","journal-title":"Current opinion in oncology"},{"key":"26","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-09-2782","article-title":"Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells","volume":"70","author":"Bost","year":"2010","journal-title":"Cancer research"},{"key":"27","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1158\/0008-5472.CAN-06-4447","article-title":"Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth","volume":"67","author":"Thompson","year":"2007","journal-title":"Cancer research"},{"key":"28","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1158\/1535-7163.MCT-13-0170","article-title":"Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib","volume":"12","author":"Leedman","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","article-title":"Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia","volume":"268","author":"Chuang","year":"2008","journal-title":"Cancer letters"},{"key":"30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/1471-2407-13-606","article-title":"Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer","volume":"13","author":"Lee","year":"2013","journal-title":"BMC Cancer"},{"key":"31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/cas.12171","article-title":"Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes","volume":"104","author":"Higashiyama","year":"2013","journal-title":"Cancer Sci"},{"key":"32","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1158\/0008-5472.CAN-06-3191","article-title":"Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL","volume":"67","author":"Chuang","year":"2007","journal-title":"Cancer Res"},{"key":"33","first-page":"ra66","article-title":"The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells","volume":"6","author":"Lauffenburger","year":"2013","journal-title":"Sci Signal"},{"key":"34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1078-0432.CCR-12-3232","article-title":"Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT","volume":"19","author":"Bivona","year":"2013","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/07357907.2012.657816","article-title":"Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells","volume":"30","author":"Jia","year":"2012","journal-title":"Cancer investigation"},{"key":"36","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1038\/sj.onc.1202788","article-title":"Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras","volume":"18","author":"Schneider","year":"1999","journal-title":"Oncogene"},{"key":"37","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1128\/MCB.15.2.614","article-title":"The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding","volume":"15","author":"Basilico","year":"1995","journal-title":"Molecular and cellular biology"},{"key":"38","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1038\/sj.onc.1201865","article-title":"Determinants for transformation induced by the Axl receptor tyrosine kinase","volume":"16","author":"Liu","year":"1998","journal-title":"Oncogene"},{"key":"39","doi-asserted-by":"crossref","first-page":"28766","DOI":"10.1074\/jbc.M401977200","article-title":"Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells","volume":"279","author":"Berk","year":"2004","journal-title":"The Journal of biological chemistry"},{"key":"40","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/1947601912462719","article-title":"Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl","volume":"3","author":"Deb","year":"2012","journal-title":"Genes & cancer"},{"key":"41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy: quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Research"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T09:30:24Z","timestamp":1599557424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.4148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,15]]},"references-count":41,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2015,6,20]]}},"alternative-id":["4148","26036314"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.4148","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,15]]}}}